News

Innomatch open call for public and private buyers

Published on | 6 months ago

Programmes EIC

InnoMatch is a EU funded project within the framework of the EIC Innovation Procurement Programma. Innomatch helps public and private buyers to find and develop tailor-made solutions together. This programme enables collaboration between buyers and innovative suppliers (EIC Awardees) to address challenges and deploy tailored solutions through a structured innovation procurement process.

The buyer will not receive direct funding but the selected EIC awardee will receive up to 60.000 euro of funding and will then try with the public buyer to develop and test a pilot solution that meets their expectations. All details can be found here and if you have any additional questions you can contact cristina.roca@iclei.org

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1709 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.